Lenrispodun/ITI-214는 강력하고 선택적인 포스포디에스터라아제1형(PDE1) 억제제이자 PDE1 포트폴리오의 대표 화합물로, ITI-214는 고리형 뉴클레오티드(cAMP, cGMP)의 분해를 억제하여 이들 분자가 세포 내에 축적되어 중요한 기능을 수행할 수 있도록 합니다. 세포 내에 축적되어 중요한 기능을 발휘할 수 있도록 합니다.
ITI-214는 임상시험에서 우수한 안전성 프로파일을 보였으며, 일반적으로 양호한 내약성을 보였습니다. 현재 ITI-214는 파킨슨병으로 인한 운동기능 변동이 있는 환자를 대상으로 한 임상 2상 시험이 진행 중이며, 심부전 치료제로도 개발되고 있습니다.
앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, ITI-214의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 파킨슨병에 대한 다른 신흥 제품들은 ITI-214와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 파킨슨병 치료제 ITI-214 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.
목차
제1장 보고서 서론
제2장 파킨슨병에서의 ITI-214 개요
- 제품 상세
- 임상 개발
- 기타 개발 활동
- 제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신흥 치료법)
제5장 ITI-214 시장 평가
- 파킨슨병용 ITI-214 시장 전망
- 주요 7개국 분석
- 주요 7개국의 파킨슨병 치료제 ITI-214 시장 규모
- 국가별 시장 분석
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight에 대해
제12장 보고서 구입 옵션
LSH
"ITI-214 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ITI-214 for Parkinson's disease in the seven major markets. A detailed picture of the ITI-214 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ITI-214 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ITI-214 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Drug Summary:
Lenrispodun/ ITI-214 is a potent and selective phosphodiesterase type 1 (PDE1) Inhibitor and is the lead compound in the company's PDE1 portfolio. ITI-214 works by blocking the breakdown of cyclic nucleotides (cAMP, cGMP), thus allowing these molecules to build up in the cells and to exert important functions.
ITI-214 has been generally well tolerated with a favorable safety profile in clinical trials. Currently, ITI-214 is being investigated in a Phase II trial in patients with motor fluctuations due to Parkinson's disease and is also being developed for the treatment of heart failure.
Scope of the Report:
The report provides insights into:
- A comprehensive product overview including the ITI-214 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
- Elaborated details on ITI-214 regulatory milestones and other development activities have been provided in this report.
- The report also highlights the ITI-214 research and development activities in Parkinson's disease across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around ITI-214.
- The report contains forecasted sales of ITI-214 for Parkinson's disease till 2032.
- Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
- The report also features the SWOT analysis with analyst views for ITI-214 in Parkinson's disease.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ITI-214 Analytical Perspective by DelveInsight
- In-depth ITI-214 Market Assessment
This report provides a detailed market assessment of ITI-214 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
- ITI-214 Clinical Assessment
The report provides the clinical trials information of ITI-214 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
- In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ITI-214 dominance.
- Other emerging products for Parkinson's disease are expected to give tough market competition to ITI-214 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ITI-214 in Parkinson's disease.
- Our in-depth analysis of the forecasted sales data of ITI-214 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ITI-214 in Parkinson's disease.
Key Questions:
- What is the product type, route of administration and mechanism of action of ITI-214?
- What is the clinical trial status of the study related to ITI-214 in Parkinson's disease and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ITI-214 development?
- What are the key designations that have been granted to ITI-214 for Parkinson's disease?
- What is the forecasted market scenario of ITI-214 for Parkinson's disease?
- What are the forecasted sales of ITI-214 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to ITI-214 for Parkinson's disease?
- Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?
Table of Contents
1. Report Introduction
2. ITI-214 Overview in Parkinson's disease
- 2.1. Product Detail
- 2.2. Clinical Development
- 2.2.1. Clinical studies
- 2.2.2. Clinical trials information
- 2.2.3. Safety and Efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. ITI-214 Market Assessment
- 5.1. Market Outlook of ITI-214 in Parkinson's disease
- 5.2. 7MM Analysis
- 5.2.1. Market Size of ITI-214 in the 7MM for Parkinson's disease
- 5.3. Country-wise Market Analysis
- 5.3.1. Market Size of ITI-214 in the United States for Parkinson's disease
- 5.3.2. Market Size of ITI-214 in Germany for Parkinson's disease
- 5.3.3. Market Size of ITI-214 in France for Parkinson's disease
- 5.3.4. Market Size of ITI-214 in Italy for Parkinson's disease
- 5.3.5. Market Size of ITI-214 in Spain for Parkinson's disease
- 5.3.6. Market Size of ITI-214 in the United Kingdom for Parkinson's disease
- 5.3.7. Market Size of ITI-214 in Japan for Parkinson's disease
6. SWOT Analysis
7. Analysts' Views
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
12. Report Purchase Options
